Xeljanz Európai Unió - lett - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinibs - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 un 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Zerbaxa Európai Unió - lett - EMA (European Medicines Agency)

zerbaxa

merck sharp & dohme b.v.  - ceftolozane sulfāts, nātrija tazobactam - bakteriālas infekcijas - antibakteriālas līdzekļi sistēmiskai lietošanai, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.

Ucedane Európai Unió - lett - EMA (European Medicines Agency)

ucedane

eurocept international bv - carglumic acid - hyperammonemia; amino acid metabolism, inborn errors - citas gremošanas trakta un metabolisma produkti, - ucedane is indicated in treatment of:hyperammonaemia due to n-acetylglutamate synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.

Etoposide-Teva 20 mg/ml koncentrāts infūziju šķīduma pagatavošanai Lettország - lett - Zāļu valsts aģentūra

etoposide-teva 20 mg/ml koncentrāts infūziju šķīduma pagatavošanai

teva pharma b.v., netherlands - etopozīds - koncentrāts infūziju šķīduma pagatavošanai - 100 mg/5 ml

Rxulti Európai Unió - lett - EMA (European Medicines Agency)

rxulti

otsuka pharmaceutical netherlands b.v. - brexpiprazole - Šizofrēnija - psihoterapija - Šizofrēnijas ārstēšanai.

Fulvestrant Stada 250 mg šķīdums injekcijām pilnšļircē Lettország - lett - Zāļu valsts aģentūra

fulvestrant stada 250 mg šķīdums injekcijām pilnšļircē

stada arzneimittel ag, germany - fulvestrants - Šķīdums injekcijām pilnšļircē - 250 mg/5 ml

Inpremzia Európai Unió - lett - EMA (European Medicines Agency)

inpremzia

baxter holding b.v. - insulin human (rdna) - cukura diabēts - cukura diabēts - inpremzia is indicated for the treatment of diabetes mellitus.

Ceftriaxone Venus Pharma 1 g pulveris injekciju/infūziju šķīduma pagatavošanai Lettország - lett - Zāļu valsts aģentūra

ceftriaxone venus pharma 1 g pulveris injekciju/infūziju šķīduma pagatavošanai

venus pharma gmbh, germany - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 1 g

Ceftriaxone Venus Pharma 2 g pulveris injekciju/infūziju šķīduma pagatavošanai Lettország - lett - Zāļu valsts aģentūra

ceftriaxone venus pharma 2 g pulveris injekciju/infūziju šķīduma pagatavošanai

venus pharma gmbh, germany - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 2 g

Onsior Európai Unió - lett - EMA (European Medicines Agency)

onsior

elanco gmbh - robenakoksibs - anti-inflammatory and anti-rheumatic products, non-steroids, coxibs - dogs; cats - kaķi (tabletes):par treatmentrelief sāpes un iekaisumu, kas saistīti ar akūto andors hroniskas balsta-kustību sistēmas traucējumi. lai samazinātu mērenas sāpes un iekaisumu, kas saistītas ar ortopēdiska operācija. suņi (tabletes):par ttreatment sāpes un iekaisumu, kas saistītas ar hronisks osteoartrīts. lai ārstētu sāpes un iekaisums, kas saistīts ar mīksto audu ķirurģija. kaķi un suņi (šķīdums injekcijām):par ttreatment sāpes un iekaisumu, kas saistītas ar ortopēdisko vai mīksto audu ķirurģija.